- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Fanconi Anemia, Aplastic Anemia
- Interventions
- anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim, therapeutic allogeneic lymphocytes, cyclophosphamide, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 4 Years to 75 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2018
- U.S. locations
- 1
- States / cities
- Buffalo, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 949
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mastocytosis
- Interventions
- Collection of blood and bone marrow
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- Not listed
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis
- Interventions
- Busulfan, Cytarabine, Fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
- Drug · Procedure · Radiation
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- Up to 69 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Glioblastoma Multiforme
- Interventions
- Surgical removal of the GBM tumor, d4-NAM infusion
- Procedure · Other
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Chronic Diabetic Foot Ulcers
- Interventions
- Extracorporeal Shockwaves
- Device
- Lead sponsor
- Tissue Regeneration Technologies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • The Bronx, New York • Akron, Ohio + 2 more
- Conditions
- Diabetes Mellitus, Sarcoidosis, Dental Caries, Sjorgren's Syndrome, Cystinosis, Head and Neck Neoplasms
- Interventions
- Not listed
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- Not listed
- Enrollment
- 264 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diabetic Foot, Pressure Ulcer, Surgical Wound Dehiscence, Vasculitis, Skin Ulcer, Leg Ulcer, Pyoderma, Peripheral Arterial Disease, Lymphedema, Surgical Complication, Venous Leg Ulcers (VLUs), Calciphylaxis, Sickle Cell Ulcer, Pressure Ulcer (PU), Diabetic Foot Ulcers (DFUs), Pressure Injury, Arterial Ulcers, Soft Tissue Radionecrosis (STRN), Traumatic Wounds, Chronic Ulcer
- Interventions
- Usual care
- Other
- Lead sponsor
- U.S. Wound Registry
- Other
- Eligibility
- Not listed
- Enrollment
- 300,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2030
- U.S. locations
- 1
- States / cities
- The Woodlands, Texas
- Conditions
- Familial Partial Lipodystrophy
- Interventions
- volanesorsen, Placebo
- Drug
- Lead sponsor
- Akcea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 6
- States / cities
- Ann Arbor, Michigan • Rochester, Minnesota • St Louis, Missouri + 3 more
- Conditions
- Breast Cancer
- Interventions
- positron emission tomography, fludeoxyglucose F 18, iodine I 124 iododeoxyuridine
- Procedure · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Insulin Resistance, Obesity
- Interventions
- Not listed
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chediak-Higashi Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 1 Month to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostate Cancer
- Interventions
- 99mTc MIP 1404, 99mTc MIP 1405
- Radiation
- Lead sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Industry
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Porphyria Cutanea Tarda
- Interventions
- Not listed
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 0 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Type 1 Diabetes,, Bone
- Interventions
- Not listed
- Lead sponsor
- Creighton University
- Other
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Hepatic Steatosis
- Interventions
- Cholic Acid
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 6 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Lipodystrophy
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 6 Months to 98 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Familial Partial Lipodystrophy
- Interventions
- Obeticholic Acid, Placebo
- Drug
- Lead sponsor
- Abhimanyu Garg
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Glucose Intolerance, Overweight and Obesity, Drug Effect, Adiposity
- Interventions
- Cyanocobalamin, Dulaglutide
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
- Interventions
- Tesamorelin
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lymphedema, Lymphatic Disorders, Lipedema, Vascular Malformation, Vascular Anomaly, Dercum Disease
- Interventions
- NIRFLI with ICG
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 3 Months and older
- Enrollment
- 283 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2030
- U.S. locations
- 3
- States / cities
- Houston, Texas • The Woodlands, Texas
- Conditions
- Insulin Resistance, Obesity
- Interventions
- INCB13739
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 2
- States / cities
- Beverly Hills, California • Chula Vista, California
- Conditions
- Lipodystrophy, Familial Partial
- Interventions
- High fat mixed meal
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Rheumatoid Arthritis, Insulin Resistance
- Interventions
- Hydroxychloroquine
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Homocystinuria Due to Cystathionine Beta-Synthase Deficiency
- Interventions
- Pegtarviliase IV, Pegtarviliase SC
- Drug
- Lead sponsor
- Aeglea Biotherapeutics
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas